Member Info for sadoldgit

well I hope it turns into a 'big one'
GLA

I concur 100%

Not sure if this is of any use with regards to patents for TYK2. I would hazard a guess that the problem with TYK2 patent is the similarity between the concept of TYK2 and Aurora FLT. I would have thought that there is sufficient difference between the two and TYK2 is not derived or tweaked as a compound from Aurora.

Of all of the forms of intellectual-property protection, patents are the most complex and tightly regulated. Patents are basically copyrights for inventions, defined by U.S. patent law as "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof." Unlike copyrights, patents protect the idea or design of the invention, rather than the tangible form of the invention itself. Consequently, patenting something is a much trickier procedure than copyrighting something.
regards all

A good read and very informative. A lot depends on the route Sierra takes, Watch this space as they say. Good find sir.

I don't think you are far out there JT. 2 directors taken on a few months ago and it It a code of practice not law as such as these 2 are not share holders do not have bias as does a share holder director. I remember talking to a retired solicitor about 3 years ago about company takeovers and deals (Poor old Tim died cancer last year) . Tim worked in company Law and dealt with such as MOD, Marconi. Plessy and a lot of others. These deals he said do not happen overnight. 18 months to 2 years he said are about the norm. As Tim has stated previously we are in talks with various interested partners. That does not mean that is 18 months to 2 years from now.

CHk 1 looks promising, TYK 2 the same but not as far advanced with regards to development. Aurora plus FLT 3 does have issues, at the same time potential, but development stopped to divert funds elsewhere. SP may drop slightly short term as when further funding or milestone payment becomes known.

Nothing spectacular of course, but I favour TYK 2, that is not to say I do not CHK1 as far more potential than perhaps we realise. It would be nice to get an update from Sierra on this but feed back on this so far has been excellent. It cannot be hurried and unfortunately this takes time. I have been here 7 years now which is not as long as some.

Big companies are looking for best in class drugs that work, the older treatments patents are expiring, generic drugs manufactured in India are a threat to big companies financial returns. The products Sareum are developing now are the treatments of the future when proven.

Not, put much of any interest really. It is also nice a couple of Pratt posters have gone quiet too.

Regards to all

PS am slightly pissed.

To post that this will drop in someone's opinion to 0.3 to 0.4p when they claim then that they will buy in for a 6 to 8 bagger which is 2.4p and then say if he were me to sell over 0.5p. Never heard so much rubbish since the days of Mr O.
On what basis Jimmy do you base that 'if this had any spunk at all it would be 3.00p' ?
What has spunk got to do with TYK2? TYK2 is a single point kinase inhibitor for the treatment of deseases not a sperm bank or some paid Thai whore in Pattaya.

Just a thought here. Would it not be better to obtain patents for these compounds towards the end of pre clinical stage to maximise the remaining patent time at the end of clinical trials?

Many patents are coming to the end of their expiry. So surely it is more financially rewarding to have a longer remaining patent life. 6 or 12 months perhaps longer must be of importance to a potential buyer. Is it feasible that this may be discussed with potential partners or am I talking out my arse?

Yes, it is still going, but dyor.

Are you related to Mr Orangeskin profit profit? Very similar traits who used to post many 10's of times of the day and constant ramping? I know it is nice to have a positive attitude but ffs don't go over the top.

All looking good to me.

September 10th 2018

Dr Tim Mitchell, CEO of Sareum, commented: “TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”

Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.



For further information, please contact:

Sareum Holdings plc

GLad sir you are bringing back a little bit of morality. Some real excrementers here tonight.

Good point sir, I believe somebody posted about the appointment of two non executive directors. should a company be approached for a bid or any other financial arrangement, although not mandatory it is a code of practice that at least half should not be any way by way of holding shares, which may give a benefit to that voter n .the board. THere was a previous posting relating to this by a previous poster with the aforementioned data. That indicates to me something is abound to happen in the not too distant future. WHat ever develops I do not have a clue, but why a point these two non executive directors.? Surely his can only send the price north. Would you rule out a complete takeover? I would notbetmyhouse against it.

SO you must remember the 10 out of 10 for mice! That should read Aurora flat plus 3 the bloody IPad I am using puts in predictive words.

Back in 2011 in went from .025p up to if memory serves me correctly a peak of 4p. That don,t sound like Alzelmers to me. YOu are telling me that you invested and predicted this jump in Feb 2011? WOW. why did you choose to buy at this point and was it for CHK1 or Aurora plus fly compound?

You are full of cobblers. Never ever did that go from .22p 5 million shares at 0.22p you sell 3 days later you make 130k profit which makes the share price 2.26p a share.. perhaps you could point me out to where this rapid increase in share price happened.when I bought at .22p it has never been near 3 p ish since. Max if memory serves me right around 1.6p

I bought a load at .22p how can I average down. Looking at this for 8 years as you claim why did you not buy then?

No money to be made at this price? You state earlier that at 0.3 to 0.4 p a 6 to 78 nagger this is only .475 p at the moment so how can you not make money at your return of 2.4p ?

Money markets are driving this down. I have noticed over .the past few days sells just after 8 am low sell but price drops 5 percent. Then later on large buys. Call me odd but the 850 k investors, are they selling early to drop the price then buying back. Many prices l think are where people have put stop losses. Christmas time people on holiday like myself and think all is ok. But underhanded forces at work. Just my opinion. Share now way way under valued and when back in U.K. Will buy, bugger a new car the old one will serve another year I hope.

Exactly my sentiments. I did have a look up on Wall Street an investment site with regards to Sierra Oncology. SHare price is down. It has a volitility score of 1.72 which is very high. It forecasts it has money in assets for short term and cash for long term, both for next 3 years. Slight hint at debt from August. Debt shown or to be more precise indicated at moment less than 40 per cent i.e. 4.6 percent. No recent data entered for year i.e. share dividends and none forecast for next 3 years. One person has purchased 66,000 shares at a cost of 108 k. I would think that Sierra Oncology want to maximise what CHK1 is capable of i.e. Advanced ovarian cancer for one. All looks ok to me. The only thing l see is perhaps when we will receive a milestone payment and this must surely be due to the amount of different cancers and differing chemosynthesis that SRA choose to put it through. I for one if I were them would max it out see what the ol gal is capable of then sell at a maximum.

Price only dropped as people choose to sell! Money markets happy to chase the his down on small volumes. 280 million shares is a lot to add and many bought at 0.2p so will perhaps have stop loss. Markets will shake out the weak or under financed